Holen Sie sich die Stockscreener-App
16.34
3.75%
0.59
Vorhandelsmarkt:
16.35
0.01
+0.06%
Schlusskurs vom Vortag:
$15.75
Offen:
$16
24-Stunden-Volumen:
686.97K
Relative Volume:
0.54
Marktkapitalisierung:
$825.93M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-156.39M
KGV:
-4.4282
EPS:
-3.69
Netto-Cashflow:
$-123.06M
1W Leistung:
+1.18%
1M Leistung:
-0.55%
6M Leistung:
+8.50%
1J Leistung:
+86.53%
1-Tages-Spanne:
$15.80
$16.79
1-Wochen-Bereich:
$15.12
$16.79
52-Wochen-Spanne:
$7.30
$17.30
Kalvista Pharmaceuticals Inc Stock (KALV) Company Profile
Firmenname
Kalvista Pharmaceuticals Inc
Sektor
Branche
Telefon
(857) 999-0075
Adresse
200 CROSSING BOULEVARD, FRAMINGHAM, MA
Vergleichen Sie KALV mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
KALV
Kalvista Pharmaceuticals Inc
|
16.34 | 796.10M | 0 | -156.39M | -123.06M | -3.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.15 | 118.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
812.27 | 81.61B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
422.50 | 53.69B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
822.94 | 49.49B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
176.00 | 37.34B | 447.02M | -1.18B | -906.14M | -6.1812 |
Kalvista Pharmaceuticals Inc Stock (KALV) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-01-31 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2025-01-07 | Eingeleitet | TD Cowen | Buy |
| 2024-12-18 | Eingeleitet | BofA Securities | Buy |
| 2020-06-15 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-07-29 | Eingeleitet | SVB Leerink | Outperform |
| 2019-03-20 | Eingeleitet | Needham | Buy |
| 2018-10-30 | Eingeleitet | Jefferies | Buy |
| 2018-09-21 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2017-08-31 | Eingeleitet | BTIG Research | Buy |
Alle ansehen
Kalvista Pharmaceuticals Inc Aktie (KALV) Neueste Nachrichten
How KalVista Pharmaceuticals Inc. (4XC1) stock moves in volatile trading sessions - bollywoodhelpline.com
Aug Sectors: Is KalVista Pharmaceuticals Inc stock supported by innovation pipeline2025 Retail Activity & Technical Buy Zone Confirmation - moha.gov.vn
Needham raises Kalvista Pharmaceuticals stock price target on Ekterly launch success - Investing.com Nigeria
KalVista Pharmaceuticals (NASDAQ:KALV) Price Target Raised to $32.00 - MarketBeat
KalVista Pharmaceuticals (KALV): Needham Raises Price Target to $32 | KALV Stock News - GuruFocus
Millennium Management LLC Acquires Additional Shares in KalVista Pharmaceuticals - GuruFocus
KalVista Pharmaceuticals Inc 4XC1 Stock Analysis and ForecastTrading Volume Trends & No Fee. No Catch. Just Smart Investment Ideas - earlytimes.in
2025 Drug Launches Underscore Commercial Headwinds For New Products - Citeline News & Insights
Precision Trading with Kalvista Pharmaceuticals Inc. (KALV) Risk Zones - Stock Traders Daily
KalVista Pharmaceuticals (NASDAQ:KALV) Trading 5.1% HigherShould You Buy? - MarketBeat
KalVista Pharmaceuticals, Inc.Common Stock (NQ: KALV - FinancialContent
KalVista Pharmaceuticals (KALV) Gains Approval for EKTERLY in Ja - GuruFocus
Japan approves KalVista’s oral HAE treatment Ekterly By Investing.com - Investing.com Canada
KalVista (KALV) Gains Approval for Ekterly in Japan - GuruFocus
KalVista Pharmaceuticals Announces Approval of EKTERLY® (sebetralstat) in Japan, First and Only Oral On-demand Treatment for Hereditary Angioedema - Business Wire
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Avoiding Lag: Real-Time Signals in (KALV) Movement - Stock Traders Daily
Will KalVista Pharmaceuticals Inc. stock attract ESG investors2025 Sector Review & Smart Money Movement Tracker - Улправда
KalVista Pharmaceuticals Earnings Notes - Trefis
KalVista Shares Navigate Post-Rally Consolidation Phase - AD HOC NEWS
Sentiment Review: How KalVista Pharmaceuticals Inc. (4XC1) stock expands through international marketsTrade Risk Assessment & Stepwise Swing Trade Plans - Улправда
Why KalVista Pharmaceuticals Inc. stock is favored by pension funds2025 Bull vs Bear & Free Community Consensus Stock Picks - DonanımHaber
Can KalVista Pharmaceuticals Inc. stock outperform in 2025 bull marketJuly 2025 Movers & Free Fast Entry Momentum Trade Alerts - DonanımHaber
Analysts Offer Insights on Healthcare Companies: KalVista Pharmaceuticals (KALV) and Novan (NOVN) - The Globe and Mail
KalVista Pharmaceuticals (NASDAQ:KALV) Reaches New 1-Year HighHere's Why - MarketBeat
OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $898,000 Stake in KalVista Pharmaceuticals, Inc. $KALV - MarketBeat
Stempoint Capital LP Cuts Stock Position in KalVista Pharmaceuticals, Inc. $KALV - MarketBeat
Discipline and Rules-Based Execution in KALV Response - news.stocktradersdaily.com
KalVista Pharmaceuticals (NASDAQ:KALV) CEO Sells $120,423.94 in Stock - MarketBeat
Possible Bearish Signals With KalVista Pharmaceuticals Insiders Disposing Stock - simplywall.st
Pharvaris surges, pulling KalVista out of a slump, on promising new HAE treatment - MSN
KalVista Pharmaceuticals (NASDAQ:KALV) Upgraded by Wall Street Zen to "Hold" Rating - MarketBeat
KalVista Pharmaceuticals (NASDAQ:KALV) Receives Buy Rating from Needham & Company LLC - MarketBeat
KalVista Pharmaceuticals, Inc. $KALV Shares Purchased by Stonepine Capital Management LLC - MarketBeat
Saturn V Capital Management LP Sells 192,267 Shares of KalVista Pharmaceuticals, Inc. $KALV - MarketBeat
Schroder Investment Management Group Has $6.27 Million Stock Holdings in KalVista Pharmaceuticals, Inc. $KALV - MarketBeat
KalVista Pharmaceuticals Executive Sells Shares to Cover Tax Obligations - TradingView
Pharvaris Stock Gains on HAE Drug Meeting Late-Stage Study Goals - sharewise.com
KalVista Pharmaceuticals (NASDAQ:KALV) Trading Up 15%Here's What Happened - MarketBeat
Panagora Asset Management Inc. Grows Stock Position in KalVista Pharmaceuticals, Inc. $KALV - MarketBeat
KalVista Pharmaceuticals (KALV) Rating Reiterated by Needham | K - GuruFocus
KalVista Pharmaceuticals (KALV) to Release Quarterly Earnings on Thursday - MarketBeat
Pharvaris’s Phase III HAE Data Position Deucrictibant For 2026 NDA Filing - Citeline News & Insights
Kalvista stock price target maintained at $30 by TD Cowen amid competitor data - Investing.com Nigeria
Biotechs Duke It Out In A Genetic Disease — And Both Surge - Investor's Business Daily
Pharvaris’ oral deucrictibant hits endpoints in acute HAE trial - BioWorld MedTech
Pharvaris Pill Provides Rapid Relief In Patients With Rare Swelling Attacks, Data Shows - Sahm
Why pension funds invest in KalVista Pharmaceuticals Inc. (4XC1) stockWeekly Profit Analysis & High Conviction Buy Zone Alerts - Newser
Will KalVista Pharmaceuticals Inc. (4XC1) stock profit from automation waveJuly 2025 Review & Safe Capital Investment Plans - Newser
KalVista Pharmaceuticals (KALV) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
How KalVista Pharmaceuticals Inc. stock reacts to inflationary pressures2025 EndofYear Setup & Free High Return Stock Watch Alerts - Newser
Finanzdaten der Kalvista Pharmaceuticals Inc-Aktie (KALV)
Umsatz
Nettogewinn
Free Cashflow
ENV
28.63%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):